Besides the cloudy economic picture in the established pharmaceutical markets, much of the current cost-cutting in pharmaceutical R&D ca...

As consolidation in RNAi Therapeutics in the Old Economies continues, the balance of power is rapidly shifting towards the resource-rich and...

Hardly a day goes by without news of delivery deals, or universities issuing a press release that their scientists have just published on a ...

Alnylam this week responded to Tekmira’s Complaint a month ago in which it alleges Alnylam to have repeatedly misappropriated and misused T...

Times have never been tougher if you are a preclinical-stage biotechnology company with a high demand for cash to support operations. At l...

( Notice : The following account is a largely hypothetical explanation of what is underlying Alnylam's current troubles) The last time A...

Not a day goes by without a lawsuit involving Alnylam. This time it would seem unjustly so. The company disclosed in a regulatory filing...